E-commerce giant makes surprise foray into diet sector, sending shares of rival wellness company tumbling.

Table of Contents Amazon has entered the obesity medication sector with significant force. The retail giant announced Tuesday its new GLP-1 treatment program via Amazon One Medical, its healthcare division, creating an all-in-one solution that combines weight management therapy with pharmaceutical services and remote medical consultations. Amazon One Medical launched a national GLP-1 weight-loss program, offering injectable treatments starting at $299 per month and oral options starting at $149 per month.$HIMS pic.twitter.com/W1sEf30uKr — Wall St Engine (@wallstengine) April 21, 2026 The initiative provides patients with branded pharmaceutical options from major manufacturers, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. For those with insurance coverage, oral GLP-1 medications are available from $25 monthly. Self-pay customers face costs starting at $149 per month for oral formulations, while injectable treatments like Wegovy and Zepbound carry a minimum monthly cost of $299. Amazon.com, Inc., AMZN While these price points align with industry standards, Amazon’s competitive advantage lies in accessibility — leveraging its established delivery infrastructure for same-day service and creating a streamlined patient experience from initial assessment through ongoing prescription management. Tanvi Patel, VP and GM of Amazon Pharmacy, emphasized that the objective is facilitating patient adherence by ensuring medications are “delivered reliably directly to patients.” The service is now operational nationwide and treats obesity as a chronic health condition requiring sustained intervention rather than short-term treatment. The program encompasses preliminary patient screening, organized medical consultations, scheduled follow-ups, and clinically-proven treatment approaches. Patients can request prescription refills on demand, with messaging consultations available for $29 and video appointments starting at $49. The company has committed to extending same-day delivery capabilities to 4,500 urban centers by year-end 2026. The revelation dealt a significant blow to Hims & Hers Health. HIMS shares declined as much as 6% during pre-market activity, with losses moderating as trading progressed. The market response underscores mounting anxiety about Amazon entering the affordable GLP-1 segment where HIMS has established its presence. The announcement arrives at a challenging moment for HIMS. The telehealth company has been pivoting toward premium-branded obesity medications — representing the higher-margin market segment — precisely as Amazon introduces a competitive integrated offering. Bank of America analysts have cautioned this development could reduce HIMS’s GLP-1 revenue stream by 31%. Additional companies in the weight management pharmaceutical sector experienced downward price movement Tuesday, including Viking Therapeutics (VKTX), Amgen (AMGN), and Septerna (SEPN). Tuesday’s announcement represents an evolution, not an introduction, of Amazon’s GLP-1 strategy. The company initiated same-day fulfillment for Novo Nordisk’s Wegovy obesity medication in January. By April, it had extended same-day delivery to Eli Lilly’s recently approved weight-loss pill, Foundayo, via its online pharmacy platform. The latest launch consolidates these separate initiatives into a unified offering — combining primary healthcare, pharmaceutical fulfillment, and telemedicine services within a single ecosystem. Analyst sentiment on Wall Street remains overwhelmingly positive for AMZN, with a Strong Buy consensus rating from 45 analysts — comprising 42 Buy ratings and 3 Hold ratings. The consensus price target of $286.74 suggests approximately 13% appreciation potential from current trading levels. AMZN shares climbed approximately 1% in response to the announcement.